Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II serelaxin in Japanese acute heart failure
jRCT2080222343Phase 2
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serelaxin in Acute Heart Failure (AHF) (3 arms), sponsored by Novartis.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on jRCT2080222343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222343.